Largest pharmaceutical companies in the United States by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 44 pharmaceutical companies in the United States ranked by total liabilities, at HUF 46.69T, ahead of Pfizer (HUF 41.31T) and Johnson & Johnson (HUF 40.04T). Figures as of 20 Nov 2026, 17:20 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- AbbVieHUF 46.69T
- Median
- HUF 283.4B
- Combined market value
- HUF 1279.2T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | HUF 46.69T | HUF 173.47T | HUF 98,138.91 | 1.71% up | 20% up | ||
| 2 | PfizerPFE · Health Care | HUF 41.31T | HUF 53.41T | HUF 9,370.63 | 0.02% down | 10% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | HUF 40.04T | HUF 221.56T | HUF 92,035.33 | 1.24% up | 31% up | ||
| 4 | Eli LillyLLY · Health Care | HUF 29.25T | HUF 410.26T | HUF 460,585.03 | 0.17% up | 28% up | ||
| 5 | Merck & CoMRK · Health Care | HUF 28.66T | HUF 113.03T | HUF 45,850.91 | 1.45% up | 36% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | HUF 24.34T | HUF 41.25T | HUF 20,179.10 | 1.64% up | 26% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | HUF 11.55T | HUF 61.38T | HUF 35,440.58 | 0.26% up | 19% down | ||
| 8 | ViatrisVTRS · Health Care | HUF 7.65T | HUF 7.6T | HUF 6,629.34 | 2.01% down | 90% up | ||
| 9 | ZoetisZTS · Health Care | HUF 4.13T | HUF 11.11T | HUF 27,354.68 | 0.51% down | 34% down | ||
| 10 | Royalty PharmaRPRX · Health Care | HUF 3.37T | HUF 13.4T | HUF 23,304.91 | 1.12% up | 74% up | ||
| 11 | Regeneron PharmaceuticalsREGN · Health Care | HUF 3.17T | HUF 32.77T | HUF 316,750.05 | 0.91% up | 22% up | ||
| 12 | Vertex PharmaceuticalsVRTX · Health Care | HUF 2.37T | HUF 45.16T | HUF 178,104.90 | 0.52% up | 22% up | ||
| 13 | Elanco Animal HealthELAN · Health Care | HUF 2.32T | HUF 4.37T | HUF 8,749.55 | 2.21% down | 18% up | ||
| 14 | Alnylam PharmaceuticalsALNY · Health Care | HUF 1.42T | HUF 6.82T | HUF 50,887.60 | 1.16% up | 66% down | ||
| 15 | Amneal PharmaceuticalsAMRX · Health Care | HUF 1.25T | HUF 2.5T | HUF 7,180.69 | 1.36% down | 79% up | ||
| 16 | PTC TherapeuticsPTCT · Health Care | HUF 1.06T | HUF 1.64T | HUF 19,605.66 | 1.23% down | 26% down | ||
| 17 | Ionis PharmaceuticalsIONS · Health Care | HUF 1.03T | HUF 1.56T | HUF 9,368.93 | 1.14% up | 64% down | ||
| 18 | BridgeBio PharmaBBIO · Health Care | HUF 1.03T | HUF 5.12T | HUF 26,260.56 | 1.30% down | 15% up | ||
| 19 | CytokineticsCYTK · Health Care | HUF 709.3B | HUF 2.44T | HUF 17,533.13 | 0.12% up | 21% down | ||
| 20 | InsmedINSM · Health Care | HUF 519.2B | HUF 10.89T | HUF 49,657.36 | 1.01% up | 27% down | ||
| 21 | BioMarin PharmaceuticalBMRN · Health Care | HUF 512.9B | HUF 4.03T | HUF 20,793.37 | 0.52% down | 12% up | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | HUF 300.1B | HUF 2.06T | HUF 14,562.16 | 1.97% down | 8% up | ||
| 23 | United TherapeuticsUTHR · Health Care | HUF 266.7B | HUF 8.04T | HUF 188,692.16 | 0.83% down | 18% up | ||
| 24 | Legend BiotechLEGN · Health Care | HUF 249B | HUF 1.02T | HUF 5,242.58 | 4.32% down | 43% down | ||
| 25 | Madrigal PharmaceuticalsMDGL · Health Care | HUF 223.6B | HUF 3.07T | HUF 132,022.58 | 2.22% down | 28% down | ||
| 26 | Axsome TherapeuticsAXSM · Health Care | HUF 204.7B | HUF 2.35T | HUF 44,595.14 | 3.42% down | 9% down | ||
| 27 | Ligand PharmaceuticalsLGND · Health Care | HUF 184.9B | HUF 1.97T | HUF 98,276.74 | 0.64% up | 44% up | ||
| 28 | Mirum PharmaceuticalsMIRM · Health Care | HUF 179.7B | HUF 2.17T | HUF 33,191.12 | 2.11% up | 35% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | HUF 166.9B | HUF 1.57T | HUF 16,398.17 | 0.24% down | 39% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | HUF 141.3B | HUF 3.32T | HUF 21,967.46 | 0.51% down | 103% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | HUF 102.5B | HUF 1.6T | HUF 9,210.68 | 2.43% down | 25% down | ||
| 32 | Rhythm PharmaceuticalsRYTM · Health Care | HUF 71.5B | HUF 2.66T | HUF 38,392.01 | 3.41% down | 15% up | ||
| 33 | Corcept TherapeuticsCORT · Health Care | HUF 64.3B | HUF 2.38T | HUF 21,729.24 | 1.74% down | 16% down | ||
| 34 | Definium TherapeuticsDFTX · Health Care | HUF 36.7B | HUF 1.35T | HUF 9,860.69 | 1.71% down | 176% up | ||
| 35 | Summit TherapeuticsSMMT · Health Care | HUF 31.4B | HUF 2.74T | HUF 3,426.99 | 4.73% down | 35% down | ||
| 36 | ErascaERAS · Health Care | HUF 24.2B | HUF 1.68T | HUF 4,784.86 | 1.13% down | 387% up | ||
| 37 | Spyre TherapeuticsSYRE · Health Care | HUF 21.3B | HUF 3.05T | HUF 32,115.72 | 3.34% down | 302% up | ||
| 38 | Praxis Precision MedicinesPRAX · Health Care | HUF 20.3B | HUF 2.91T | HUF 104,177.84 | 1.54% down | 83% up | ||
| 39 | Protagonist TherapeuticsPTGX · Health Care | HUF 18.2B | HUF 2.71T | HUF 41,544.20 | 1.57% down | 45% up | ||
| 40 | Dianthus TherapeuticsDNTH · Health Care | HUF 12.8B | HUF 1.61T | HUF 28,670.01 | 0.69% down | 105% up | ||
| 41 | Edgewise TherapeuticsEWTX · Health Care | HUF 10.3B | HUF 1.5T | HUF 13,679.04 | 2.37% down | 82% up | ||
| 42 | Oruka TherapeuticsORKA · Health Care | HUF 5.7B | HUF 2.18T | HUF 32,110.61 | 3.30% down | 233% up | ||
| 43 | Belite BioBLTE · Health Care | HUF 3.4B | HUF 1.77T | HUF 43,638.85 | 15.09% down | 25% up | ||
| 44 | VeradermicsMANE · Health Care | HUF 3.1B | HUF 1.73T | HUF 40,916.31 | 3.34% down | 230% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 340.3 HUF).
Questions and answers
Which pharmaceutical companies in the United States rank first by total liabilities?
AbbVie (HUF 46.69T), Pfizer (HUF 41.31T) and Johnson & Johnson (HUF 40.04T) are the top three of the 44 pharmaceutical companies in the United States ranked by total liabilities as of 20 Nov 2026, 17:20 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by total liabilities.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by total liabilities have a combined market value of HUF 1279.2T as of 20 Nov 2026, 17:20 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total liabilities”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.